These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 7719074

  • 1. [Ocular findings in Desferal therapy].
    Dennerlein JA, Lang GE, Stahnke K, Kleihauer E, Lang GK.
    Ophthalmologe; 1995 Feb; 92(1):38-42. PubMed ID: 7719074
    [Abstract] [Full Text] [Related]

  • 2. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS, Lam WC, Kirby M, Chun A.
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [Abstract] [Full Text] [Related]

  • 3. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
    Viola F, Barteselli G, Dell'arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R.
    Ophthalmology; 2012 Aug; 119(8):1693-700. PubMed ID: 22480740
    [Abstract] [Full Text] [Related]

  • 4. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
    Spraul CW, Schicketanz C, Lang GE.
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
    [Abstract] [Full Text] [Related]

  • 5. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy.
    Tyni T, Kivelä T, Lappi M, Summanen P, Nikoskelainen E, Pihko H.
    Ophthalmology; 1998 May; 105(5):810-24. PubMed ID: 9593380
    [Abstract] [Full Text] [Related]

  • 6. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M, Meleleo D, Tricarico N, Greco Miani A, Serra E, Parlatore L.
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [Abstract] [Full Text] [Related]

  • 8. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 May; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 9. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 10. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 11. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanomas.
    Prager TC, Kellaway J, Zou Y, Urso RG, McIntyre S, Bedikian AY.
    Anticancer Drugs; 1998 Jul; 9(6):515-24. PubMed ID: 9877239
    [Abstract] [Full Text] [Related]

  • 13. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Jul; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 14. [Ocular toxicity of deferoxamine: description and analysis of three observations].
    Szwarcberg J, Mack G, Flament J.
    J Fr Ophtalmol; 2002 Jun; 25(6):609-14. PubMed ID: 12223949
    [Abstract] [Full Text] [Related]

  • 15. [Retinal pigment epithelium--desferal].
    Roulez F.
    Bull Soc Belge Ophtalmol; 2007 Jun; (304):59-66. PubMed ID: 17718228
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ocular manifestations of HIV infection.
    Jabs DA.
    Trans Am Ophthalmol Soc; 1995 Jun; 93():623-83. PubMed ID: 8719695
    [Abstract] [Full Text] [Related]

  • 18. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 19. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF.
    Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
    [Abstract] [Full Text] [Related]

  • 20. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F, Monnier N, Dufier JL, Réveillaud RJ.
    Nephrologie; 1987 Oct; 8(1):27-9. PubMed ID: 3587485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.